-
1
-
-
0003964363
-
-
American Cancer Society. Atlanta: Am. Cancer Soc. 2013
-
American Cancer Society. 2013. Cancer Facts & Figures 2013. Atlanta: Am. Cancer Soc.
-
(2013)
Cancer Facts & Figures
-
-
-
3
-
-
0026031848
-
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
-
Lipshultz SE, Colan SD, Gelber RD, et al. 1991. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324:808-15
-
(1991)
N. Engl. J. Med.
, vol.324
, pp. 808-815
-
-
Lipshultz, S.E.1
Colan, S.D.2
Gelber, R.D.3
-
4
-
-
84870055817
-
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort
-
Mulrooney DA, YeazelMW, KawashimaT, et al. 2009. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606
-
(2009)
BMJ
, vol.339
, pp. b4606
-
-
Mulrooney, D.A.1
Yeazel, M.W.2
Kawashima, T.3
-
5
-
-
33749599695
-
Chronic health conditions in adult survivors of childhood cancer
-
Oeffinger KC, Mertens AC, Sklar CA, et al. 2006. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355:1572-82
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 1572-1582
-
-
Oeffinger, K.C.1
Mertens, A.C.2
Sklar, C.A.3
-
6
-
-
53249111431
-
Cause-specific late mortality among 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study
-
Mertens AC, Liu Q, Neglia JP, et al. 2008. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J. Natl. Cancer Inst. 100:1368-79
-
(2008)
J. Natl. Cancer Inst.
, vol.100
, pp. 1368-1379
-
-
Mertens, A.C.1
Liu, Q.2
Neglia, J.P.3
-
7
-
-
77950464739
-
Cardiotoxicity after childhood cancer: Beginning with the end in mind
-
Lipshultz SE, Adams MJ. 2010. Cardiotoxicity after childhood cancer: beginning with the end in mind. J. Clin. Oncol. 28:1276-81
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1276-1281
-
-
Lipshultz, S.E.1
Adams, M.J.2
-
8
-
-
77950498795
-
Role of cancer treatment in long-Term overall and cardiovascular mortality after childhood cancer
-
Tukenova M, Guibout C, Oberlin O, et al. 2010. Role of cancer treatment in long-Term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol. 28:1308-15
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1308-1315
-
-
Tukenova, M.1
Guibout, C.2
Oberlin, O.3
-
9
-
-
0035398020
-
Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study
-
Mertens AC, Yasui Y, Neglia JP, et al. 2001. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J. Clin. Oncol. 19:3163-72
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 3163-3172
-
-
Mertens, A.C.1
Yasui, Y.2
Neglia, J.P.3
-
10
-
-
77954582454
-
Long-Term cause-specific mortality among survivors of childhood cancer
-
Reulen RC, Winter DL, Frobisher C, et al. 2010. Long-Term cause-specific mortality among survivors of childhood cancer. JAMA 304:172-79
-
(2010)
JAMA
, vol.304
, pp. 172-179
-
-
Reulen, R.C.1
Winter, D.L.2
Frobisher, C.3
-
11
-
-
0031894189
-
Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia
-
Nysom K, Holm K, Lipsitz SR, et al. 1998. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 16:545-50
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 545-550
-
-
Nysom, K.1
Holm, K.2
Lipsitz, S.R.3
-
12
-
-
18444416815
-
Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia
-
Lipshultz SE, Lipsitz SR, Sallan SE, et al. 2005. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23:2629-36
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 2629-2636
-
-
Lipshultz, S.E.1
Lipsitz, S.R.2
Sallan, S.E.3
-
13
-
-
0035990041
-
Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review
-
Kremer LC, van der Pal HJ, OffringaM, et al. 2002. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol. 13:819-29
-
(2002)
Ann. Oncol.
, vol.13
, pp. 819-829
-
-
Kremer, L.C.1
Van Der Pal, H.J.2
Offringa, M.3
-
14
-
-
18244372155
-
Pathophysiology of anthracycline-And radiation-Associated cardiomyopathies: Implications for screening and prevention
-
Adams MJ, Lipshultz SE. 2005. Pathophysiology of anthracycline-And radiation-Associated cardiomyopathies: implications for screening and prevention. Pediatr. Blood Cancer 44:600-6
-
(2005)
Pediatr. Blood Cancer
, vol.44
, pp. 600-606
-
-
Adams, M.J.1
Lipshultz, S.E.2
-
15
-
-
84921406669
-
Effect of dexrazoxane on impaired mitochondrial structure and function in doxorubicin-Treated childhood ALL survivors
-
Abstr.) Suppl.
-
Lipshultz SE, Miller TL, GerschensonM, et al. 2012. Effect of dexrazoxane on impaired mitochondrial structure and function in doxorubicin-Treated childhood ALL survivors. J. Clin. Oncol. 30(Suppl.):9530 (Abstr.)
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 9530
-
-
Lipshultz, S.E.1
Miller, T.L.2
Gerschenson, M.3
-
16
-
-
14944358230
-
Clinical significance of cyclophosphamide-induced cardiotoxicity
-
Taniguchi I. 2005. Clinical significance of cyclophosphamide-induced cardiotoxicity. Intern.Med. 44:89-90
-
(2005)
Intern.Med.
, vol.44
, pp. 89-90
-
-
Taniguchi, I.1
-
17
-
-
34347395733
-
Trastuzumab-mechanism of action and use in clinical practice
-
Hudis CA. 2007. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357:39-51
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 39-51
-
-
Hudis, C.A.1
-
18
-
-
52049104951
-
A phase i study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors
-
Albanell J, Montagut C, Jones ET, et al. 2008. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin. Cancer Res. 14:2726-31
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 2726-2731
-
-
Albanell, J.1
Montagut, C.2
Jones, E.T.3
-
19
-
-
74049164266
-
The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy
-
De Keulenaer GW, Doggen K, Lemmens K. 2010. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ. Res. 106:35-46
-
(2010)
Circ. Res.
, vol.106
, pp. 35-46
-
-
De Keulenaer, G.W.1
Doggen, K.2
Lemmens, K.3
-
20
-
-
84866060182
-
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study
-
Bowles EJ, Wellman R, Feigelson HS, et al. 2012. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl. Cancer Inst. 104:1293-305
-
(2012)
J. Natl. Cancer Inst.
, vol.104
, pp. 1293-1305
-
-
Bowles, E.J.1
Wellman, R.2
Feigelson, H.S.3
-
21
-
-
32144448027
-
Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment
-
Ewer MS, Vooletich MT, Durand JB, et al. 2005. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23:7820-26
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 7820-7826
-
-
Ewer, M.S.1
Vooletich, M.T.2
Durand, J.B.3
-
22
-
-
84864044404
-
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the Children's Oncology Group
-
Ebb D, Meyers P, Grier H, et al. 2012. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group. J. Clin. Oncol. 30:2545-51
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 2545-2551
-
-
Ebb, D.1
Meyers, P.2
Grier, H.3
-
23
-
-
44949253343
-
Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials
-
Perez EA, Koehler M, Byrne J, et al. 2008. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83:679-86
-
(2008)
Mayo Clin. Proc.
, vol.83
, pp. 679-686
-
-
Perez, E.A.1
Koehler, M.2
Byrne, J.3
-
24
-
-
77957961667
-
Phase i trial of lapatinib in children with refractory CNS malignancies: A Pediatric Brain Tumor Consortium study
-
FouladiM, Stewart CF, Blaney SM, et al. 2010. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J. Clin. Oncol. 28:4221-27
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 4221-4227
-
-
Fouladi, M.1
Stewart, C.F.2
Blaney, S.M.3
-
25
-
-
79955040838
-
Treatment of pediatric chronic myeloid leukemia in the year 2010: Use of tyrosine kinase inhibitors and stem-cell transplantation
-
Suttorp M, Millot F. 2010. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematol. Am. Soc. Hematol. Educ. Program 2010:368-76
-
(2010)
Hematol. Am. Soc. Hematol. Educ. Program
, vol.2010
, pp. 368-376
-
-
Suttorp, M.1
Millot, F.2
-
26
-
-
33746845181
-
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
-
Kerkela R, Grazette L, Yacobi R, et al. 2006. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12:908-16
-
(2006)
Nat. Med.
, vol.12
, pp. 908-916
-
-
Kerkela, R.1
Grazette, L.2
Yacobi, R.3
-
27
-
-
34548030470
-
Congestive heart failure is a rare event in patients receiving imatinib therapy
-
Atallah E, Durand JB, Kantarjian H, Cortes J. 2007. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110:1233-37
-
(2007)
Blood
, vol.110
, pp. 1233-1237
-
-
Atallah, E.1
Durand, J.B.2
Kantarjian, H.3
Cortes, J.4
-
28
-
-
37549041711
-
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study
-
Bond M, Bernstein ML, Pappo A, et al. 2008. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer 50:254-58
-
(2008)
Pediatr. Blood Cancer
, vol.50
, pp. 254-258
-
-
Bond, M.1
Bernstein, M.L.2
Pappo, A.3
-
29
-
-
70449711127
-
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study
-
Schultz KR, Bowman WP, Aledo A, et al. 2009. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J. Clin. Oncol. 27:5175-81
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 5175-5181
-
-
Schultz, K.R.1
Bowman, W.P.2
Aledo, A.3
-
30
-
-
82355169061
-
A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat
-
Herman EH, Knapton A, Rosen E, et al. 2011. A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol. Pathol. 39:1091-106
-
(2011)
Toxicol. Pathol.
, vol.39
, pp. 1091-1106
-
-
Herman, E.H.1
Knapton, A.2
Rosen, E.3
-
31
-
-
84873529136
-
Dasatinib, nilotinib and standard-dose imatinib for the firstline treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses
-
Pavey T, Hoyle M, Ciani O, et al. 2012. Dasatinib, nilotinib and standard-dose imatinib for the firstline treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol. Assess. 16(42):1-277
-
(2012)
Health Technol. Assess.
, vol.16
, Issue.42
, pp. 1-277
-
-
Pavey, T.1
Hoyle, M.2
Ciani, O.3
-
33
-
-
84883741352
-
Nilotinib treatment-Associated accelerated atherosclerosis: When is the risk justified?
-
Tefferi A. 2013. Nilotinib treatment-Associated accelerated atherosclerosis: When is the risk justified?. Leukemia 27:1939-40
-
(2013)
Leukemia
, vol.27
, pp. 1939-1940
-
-
Tefferi, A.1
-
34
-
-
84887076805
-
Cancer-drug discovery and cardiovascular surveillance
-
Groarke JD, Cheng S, Moslehi J. 2013. Cancer-drug discovery and cardiovascular surveillance. N. Engl. J. Med. 369:1779-81
-
(2013)
N. Engl. J. Med.
, vol.369
, pp. 1779-1781
-
-
Groarke, J.D.1
Cheng, S.2
Moslehi, J.3
-
35
-
-
84875886935
-
Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
-
Bair SM, ChoueiriTK, Moslehi J. 2013. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc. Med. 23:104-13
-
(2013)
Trends Cardiovasc. Med.
, vol.23
, pp. 104-113
-
-
Bair, S.M.1
Choueiri, T.K.2
Moslehi, J.3
-
36
-
-
79955767772
-
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib
-
Rini BI, Cohen DP, LuDR, et al. 2011. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 103:763-73
-
(2011)
J. Natl. Cancer Inst.
, vol.103
, pp. 763-773
-
-
Rini, B.I.1
Cohen, D.P.2
Lu, D.R.3
-
37
-
-
36849023013
-
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
-
Chu TF, Rupnick MA, Kerkela R, et al. 2007. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-19
-
(2007)
Lancet
, vol.370
, pp. 2011-2019
-
-
Chu, T.F.1
Rupnick, M.A.2
Kerkela, R.3
-
38
-
-
50849094516
-
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
-
Telli ML, Witteles RM, Fisher GA, Srinivas S. 2008. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol. 19:1613-18
-
(2008)
Ann. Oncol.
, vol.19
, pp. 1613-1618
-
-
Telli, M.L.1
Witteles, R.M.2
Fisher, G.A.3
Srinivas, S.4
-
39
-
-
55949123335
-
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
-
Schmidinger M, Zielinski CC, Vogl UM, et al. 2008. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26:5204-12
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 5204-5212
-
-
Schmidinger, M.1
Zielinski, C.C.2
Vogl, U.M.3
-
40
-
-
79960983264
-
Phase i and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A Children's Oncology Group study
-
Dubois SG, Shusterman S, Ingle AM, et al. 2011. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Clin. Cancer Res. 17:5113-22
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 5113-5122
-
-
Dubois, S.G.1
Shusterman, S.2
Ingle, A.M.3
-
41
-
-
80052017961
-
Phase i pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia
-
Inaba H, Rubnitz JE, Coustan-Smith E, et al. 2011. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J. Clin. Oncol. 29:3293-300
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 3293-3300
-
-
Inaba, H.1
Rubnitz, J.E.2
Coustan-Smith, E.3
-
42
-
-
84868543745
-
A phase i trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: A Children's Oncology Group Phase i Consortium report
-
Widemann BC, Kim A, Fox E, et al. 2012. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin. Cancer Res. 18:6011-22
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 6011-6022
-
-
Widemann, B.C.1
Kim, A.2
Fox, E.3
-
43
-
-
0026513214
-
Coronary artery disease mortality in patients treated for Hodgkin's disease
-
Boivin JF, Hutchison GB, Lubin JH, Mauch P. 1992. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69:1241-47
-
(1992)
Cancer
, vol.69
, pp. 1241-1247
-
-
Boivin, J.F.1
Hutchison, G.B.2
Lubin, J.H.3
Mauch, P.4
-
44
-
-
4143078308
-
Cardiovascular status in long-Term survivors of Hodgkin's disease treated with chest radiotherapy
-
AdamsMJ, Lipsitz SR, Colan SD, et al. 2004. Cardiovascular status in long-Term survivors of Hodgkin's disease treated with chest radiotherapy. J. Clin. Oncol. 22:3139-48
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 3139-3148
-
-
Adams, M.J.1
Lipsitz, S.R.2
Colan, S.D.3
-
45
-
-
84879504038
-
Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
-
Landy DC, Miller TL, Lipsitz SR, et al. 2013. Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr. Cardiol. 34:826-34
-
(2013)
Pediatr. Cardiol.
, vol.34
, pp. 826-834
-
-
Landy, D.C.1
Miller, T.L.2
Lipsitz, S.R.3
-
46
-
-
84861763781
-
Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy
-
Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. 2012. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J. Clin. Oncol. 30:1050-57
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 1050-1057
-
-
Lipshultz, S.E.1
Landy, D.C.2
Lopez-Mitnik, G.3
-
47
-
-
41149115636
-
Anthracycline associated cardiotoxicity in survivors of childhood cancer
-
Lipshultz SE, Alvarez JA, Scully RE. 2008. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525-33
-
(2008)
Heart
, vol.94
, pp. 525-533
-
-
Lipshultz, S.E.1
Alvarez, J.A.2
Scully, R.E.3
-
48
-
-
0035155497
-
Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-Term follow-up study
-
Kremer LC, van Dalen EC, Offringa M, et al. 2001. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-Term follow-up study. J. Clin. Oncol. 19:191-96
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 191-196
-
-
Kremer, L.C.1
Van Dalen, E.C.2
Offringa, M.3
-
49
-
-
79953732943
-
Anthracycline-Associated cardiotoxicity in survivors of childhood cancer
-
TrachtenbergBH, LandyDC, Franco VI, et al. 2011. Anthracycline-Associated cardiotoxicity in survivors of childhood cancer. Pediatr. Cardiol. 32:342-53
-
(2011)
Pediatr. Cardiol.
, vol.32
, pp. 342-353
-
-
Trachtenberg, B.H.1
Landy, D.C.2
Franco, V.I.3
-
50
-
-
84876494771
-
Ethnic group differences in cardiometabolic disease risk factors independent of body mass index among American youth
-
Messiah SE, Arheart KL, Lopez-Mitnik G, et al. 2013. Ethnic group differences in cardiometabolic disease risk factors independent of body mass index among American youth. Obesity 21:424-28
-
(2013)
Obesity
, vol.21
, pp. 424-428
-
-
Messiah, S.E.1
Arheart, K.L.2
Lopez-Mitnik, G.3
-
51
-
-
84856509803
-
Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
-
Landy DC, Miller TL, Lopez-Mitnik G, et al. 2012. Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Am. Heart J. 163:295-301.e2
-
(2012)
Am. Heart J.
, vol.163
, pp. 295-295e2
-
-
Landy, D.C.1
Miller, T.L.2
Lopez-Mitnik, G.3
-
52
-
-
65649091719
-
Predictors of inactive lifestyle among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
-
Ness KK, Leisenring WM, Huang S, et al. 2009. Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer 115:1984-94
-
(2009)
Cancer
, vol.115
, pp. 1984-1994
-
-
Ness, K.K.1
Leisenring, W.M.2
Huang, S.3
-
53
-
-
84873714954
-
Exercise capacity in long-Term survivors of pediatric cancer: An analysis from the Cardiac Risk Factors inChildhood Cancer Survivors Study
-
Miller AM, Lopez-Mitnik G, Somarriba G, et al. 2013. Exercise capacity in long-Term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors inChildhood Cancer Survivors Study. Pediatr. Blood Cancer 60:663-68
-
(2013)
Pediatr. Blood Cancer
, vol.60
, pp. 663-668
-
-
Miller, A.M.1
Lopez-Mitnik, G.2
Somarriba, G.3
-
54
-
-
84884908105
-
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-Treated survivors of childhood high-risk leukemia
-
Lipshultz SE, Lipsitz SR, Kutok JL, et al. 2013. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-Treated survivors of childhood high-risk leukemia. Cancer 119:3555-62
-
(2013)
Cancer
, vol.119
, pp. 3555-3562
-
-
Lipshultz, S.E.1
Lipsitz, S.R.2
Kutok, J.L.3
-
55
-
-
46049104446
-
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer
-
Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. 2008. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789-95
-
(2008)
Cancer
, vol.112
, pp. 2789-2795
-
-
Blanco, J.G.1
Leisenring, W.M.2
Gonzalez-Covarrubias, V.M.3
-
56
-
-
81855225220
-
Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group
-
Blanco JG, Sun CL, Landier W, et al. 2012. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group. J. Clin. Oncol. 30:1415-21
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 1415-1421
-
-
Blanco, J.G.1
Sun, C.L.2
Landier, W.3
-
57
-
-
84863001655
-
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children
-
Visscher H, Ross CJ, Rassekh SR, et al. 2012. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30:1422-28
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 1422-1428
-
-
Visscher, H.1
Ross, C.J.2
Rassekh, S.R.3
-
58
-
-
84879219119
-
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children
-
VisscherH, Ross CJ, Rassekh SR, et al. 2013. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr. Blood Cancer 60:1375-81
-
(2013)
Pediatr. Blood Cancer
, vol.60
, pp. 1375-1381
-
-
Visscher, H.1
Ross, C.J.2
Rassekh, S.R.3
-
59
-
-
0141816698
-
Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin
-
Miranda CJ, Makui H, Soares RJ, et al. 2003. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102:2574-80
-
(2003)
Blood
, vol.102
, pp. 2574-2580
-
-
Miranda, C.J.1
Makui, H.2
Soares, R.J.3
-
60
-
-
0030071262
-
Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children
-
Lipshultz SE. 1996. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J. Clin. Oncol. 14:328-31
-
(1996)
J. Clin. Oncol.
, vol.14
, pp. 328-331
-
-
Lipshultz, S.E.1
-
61
-
-
77957355941
-
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-Treated children with high-risk acute lymphoblastic leukaemia: Long-Term follow-up of a prospective, randomized, multicentre trial
-
Lipshultz SE, Scully RE, Lipsitz SR, et al. 2010. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-Treated children with high-risk acute lymphoblastic leukaemia: long-Term follow-up of a prospective, randomized, multicentre trial. Lancet Oncol. 11:950-61
-
(2010)
Lancet Oncol.
, vol.11
, pp. 950-961
-
-
Lipshultz, S.E.1
Scully, R.E.2
Lipsitz, S.R.3
-
62
-
-
9044233260
-
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin
-
Wexler LH, Andrich MP, Venzon D, et al. 1996. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 14:362-72
-
(1996)
J. Clin. Oncol. 62
, vol.14
, pp. 362-372
-
-
Wexler, L.H.1
Andrich, M.P.2
Venzon, D.3
-
64
-
-
3042850886
-
The effect of dexrazoxane on myocardial injury in doxorubicin-Treated children with acute lymphoblastic leukemia
-
Lipshultz SE, Rifai N, Dalton VM, et al. 2004. The effect of dexrazoxane on myocardial injury in doxorubicin-Treated children with acute lymphoblastic leukemia. N. Engl. J. Med. 351:145-53
-
(2004)
N. Engl. J. Med.
, vol.351
, pp. 145-153
-
-
Lipshultz, S.E.1
Rifai, N.2
Dalton, V.M.3
-
65
-
-
84921414996
-
Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosedT-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL)
-
Abstr.) Suppl.
-
Asselin B, DevidasM, ZhouT, et al. 2012. Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosedT-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL). J. Clin. Oncol. 30(Suppl.):9504 (Abstr.)
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 9504
-
-
Asselin, B.1
Devidas, M.2
Zhou, T.3
-
66
-
-
84907485198
-
The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-Treated patients with osteosarcoma (OS)
-
Abstr.) Suppl.
-
Kopp LM, Bernstein ML, Schwartz CL, et al. 2012. The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-Treated patients with osteosarcoma (OS). J. Clin. Oncol. 30(Suppl.):9503 (Abstr.)
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 9503
-
-
Kopp, L.M.1
Bernstein, M.L.2
Schwartz, C.L.3
-
67
-
-
84873722765
-
Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the Pediatric Health Information Systems database
-
Walker DM, Fisher BT, Seif AE, et al. 2013. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr. Blood Cancer 60:616-20
-
(2013)
Pediatr. Blood Cancer
, vol.60
, pp. 616-620
-
-
Walker, D.M.1
Fisher, B.T.2
Seif, A.E.3
-
68
-
-
34547677730
-
Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: A claim without compelling evidence
-
author reply 3180
-
Lipshultz SE, Lipsitz SR, Orav EJ. 2007. Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence. J. Clin. Oncol. 25:3179; author reply 3180
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 3179
-
-
Lipshultz, S.E.1
Lipsitz, S.R.2
Orav, E.J.3
-
69
-
-
35648964243
-
Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: A claim without evidence
-
4689-90; author reply
-
Hellmann K. 2007. Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. J. Clin. Oncol. 25:4689-90; author reply 90-91
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 90-91
-
-
Hellmann, K.1
-
70
-
-
33845402341
-
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
-
Cardinale D, Colombo A, Sandri MT, et al. 2006. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-81
-
(2006)
Circulation
, vol.114
, pp. 2474-2481
-
-
Cardinale, D.1
Colombo, A.2
Sandri, M.T.3
-
71
-
-
41949096690
-
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
-
Barry EV, Vrooman LM, Dahlberg SE, et al. 2008. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J. Clin. Oncol. 26:1106-11
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 1106-1111
-
-
Barry, E.V.1
Vrooman, L.M.2
Dahlberg, S.E.3
-
72
-
-
84921406668
-
Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence
-
In press. doi: 101016/j.ppedcard.2014.09.007
-
Lipshultz SE, Franco VI, Sallan SE, et al. 2014. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence. Prog. Pediatr. Cardiol. In press. doi: 101016/j.ppedcard.2014.09.007
-
(2014)
Prog. Pediatr. Cardiol
-
-
Lipshultz, S.E.1
Franco, V.I.2
Sallan, S.E.3
-
73
-
-
79957557043
-
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium
-
Vrooman LM, Neuberg DS, Stevenson KE, et al. 2011. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur. J. Cancer 47:1373-79
-
(2011)
Eur. J. Cancer
, vol.47
, pp. 1373-1379
-
-
Vrooman, L.M.1
Neuberg, D.S.2
Stevenson, K.E.3
-
74
-
-
76749108960
-
Long-Term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001 a report from the Children's Oncology Group
-
Salzer WL, Devidas M, Carroll WL, et al. 2010. Long-Term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children's Oncology Group. Leukemia 24:355-70
-
(2010)
Leukemia
, vol.24
, pp. 355-370
-
-
Salzer, W.L.1
Devidas, M.2
Carroll, W.L.3
-
75
-
-
84921406668
-
Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence
-
Lipshultz SE, Franco VI, Sallan SE, et al. 2014. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence. Prog. Pediatr. Cardiol. 36:39-49
-
(2014)
Prog. Pediatr. Cardiol.
, vol.36
, pp. 39-49
-
-
Lipshultz, S.E.1
Franco, V.I.2
Sallan, S.E.3
-
76
-
-
33947542048
-
Dexrazoxane-Associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
-
Tebbi CK, London WB, Friedman D, et al. 2007. Dexrazoxane-Associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol. 25:493-500
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 493-500
-
-
Tebbi, C.K.1
London, W.B.2
Friedman, D.3
-
77
-
-
84867375691
-
Response-dependent and reduced treatment in lower riskHodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group
-
Tebbi CK, Mendenhall NP, London WB, et al. 2012. Response-dependent and reduced treatment in lower riskHodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr. Blood Cancer 59:1259-65
-
(2012)
Pediatr. Blood Cancer
, vol.59
, pp. 1259-1265
-
-
Tebbi, C.K.1
Mendenhall, N.P.2
London, W.B.3
-
78
-
-
70349260655
-
A risk-Adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-And high-risk Hodgkin lymphoma: The results of P9425
-
Schwartz CL, Constine LS, Villaluna D, et al. 2009. A risk-Adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-And high-risk Hodgkin lymphoma: the results of P9425. Blood 114:2051-59
-
(2009)
Blood
, vol.114
, pp. 2051-2059
-
-
Schwartz, C.L.1
Constine, L.S.2
Villaluna, D.3
-
79
-
-
84921355260
-
Late mortality and relapse after dexrazoxane (DRZ) treatment: An update from the Children's Oncology Group (COG)
-
Abstr.) Suppl.
-
Chow EJ, Asselin B, Schwartz CL, et al. 2014. Late mortality and relapse after dexrazoxane (DRZ) treatment: an update from the Children's Oncology Group (COG). J. Clin. Oncol. 32(Suppl.):10024 (Abstr.)
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. 10024
-
-
Chow, E.J.1
Asselin, B.2
Schwartz, C.L.3
-
80
-
-
84870555288
-
Continuous versus bolus infusion of doxorubicin in children with ALL: Long-Term cardiac outcomes
-
Lipshultz SE, Miller TL, Lipsitz SR, et al. 2012. Continuous versus bolus infusion of doxorubicin in children with ALL: long-Term cardiac outcomes. Pediatrics 130:1003-11
-
(2012)
Pediatrics
, vol.130
, pp. 1003-1011
-
-
Lipshultz, S.E.1
Miller, T.L.2
Lipsitz, S.R.3
-
81
-
-
1242292932
-
Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br
-
Levitt GA, Dorup I, Sorensen K, Sullivan I. 2004. Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br. J. Haematol. 124:463-68
-
(2004)
J. Haematol.
, vol.124
, pp. 463-468
-
-
Levitt, G.A.1
Dorup, I.2
Sorensen, K.3
Sullivan, I.4
-
82
-
-
0037410353
-
Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers
-
GuptaM, Steinherz PG, Cheung NK, Steinherz L. 2003. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med. Pediatr. Oncol. 40:343-47
-
(2003)
Med. Pediatr. Oncol.
, vol.40
, pp. 343-347
-
-
Gupta, M.1
Steinherz, P.G.2
Cheung, N.K.3
Steinherz, L.4
-
83
-
-
0037087687
-
Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol
-
Lipshultz SE, Giantris AL, Lipsitz SR, et al. 2002. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J. Clin. Oncol. 20:1677-82
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 1677-1682
-
-
Lipshultz, S.E.1
Giantris, A.L.2
Lipsitz, S.R.3
-
84
-
-
0025913812
-
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
-
SOLVD Investig.
-
SOLVD Investig. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325:293-302
-
(1991)
N. Engl. J. Med.
, vol.325
, pp. 293-302
-
-
-
85
-
-
0036895164
-
Long-Term enalapril therapy for left ventricular dysfunction in doxorubicin-Treated survivors of childhood cancer
-
Lipshultz SE, Lipsitz SR, Sallan SE, et al. 2002. Long-Term enalapril therapy for left ventricular dysfunction in doxorubicin-Treated survivors of childhood cancer. J. Clin. Oncol. 20:4517-22
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 4517-4522
-
-
Lipshultz, S.E.1
Lipsitz, S.R.2
Sallan, S.E.3
-
86
-
-
1542608355
-
Enalapril to prevent cardiac function decline in long-Term survivors of pediatric cancer exposed to anthracyclines
-
Silber JH, Cnaan A, Clark BJ, et al. 2004. Enalapril to prevent cardiac function decline in long-Term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 22:820-28
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 820-828
-
-
Silber, J.H.1
Cnaan, A.2
Clark, B.J.3
-
87
-
-
33644806519
-
Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies
-
Wouters KA, Kremer LC, Miller TL, et al. 2005. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131:561-78
-
(2005)
Br. J. Haematol.
, vol.131
, pp. 561-578
-
-
Wouters, K.A.1
Kremer, L.C.2
Miller, T.L.3
-
89
-
-
84861779336
-
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-Term echocardiographic outcomes
-
Lipshultz SE, Miller TL, Scully RE, et al. 2012. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-Term echocardiographic outcomes. J. Clin. Oncol. 30:1042-49
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 1042-1049
-
-
Lipshultz, S.E.1
Miller, T.L.2
Scully, R.E.3
-
90
-
-
84878731843
-
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients withmalignant hemopathies: TheOVERCOMEtrial (prevention of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)
-
Bosch X, RoviraM, SitgesM, et al. 2013. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients withmalignant hemopathies: theOVERCOMEtrial (prevention of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 61(23):2355-62
-
(2013)
J. Am. Coll. Cardiol.
, vol.61
, Issue.23
, pp. 2355-2362
-
-
Bosch, X.1
Rovira, M.2
Sitges, M.3
-
91
-
-
7044229575
-
Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure
-
Sliwa K, Norton GR, Kone N, et al. 2004. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J. Am. Coll. Cardiol. 44:1825-30
-
(2004)
J. Am. Coll. Cardiol.
, vol.44
, pp. 1825-1830
-
-
Sliwa, K.1
Norton, G.R.2
Kone, N.3
-
93
-
-
5144228674
-
Pediatric heart transplantation for anthracycline cardiomyopathy: Cancer recurrence is rare
-
Ward KM, Binns H, Chin C, et al. 2004. Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. J. Heart Lung Transplant. 23:1040-45
-
(2004)
J. Heart Lung Transplant.
, vol.23
, pp. 1040-1045
-
-
Ward, K.M.1
Binns, H.2
Chin, C.3
-
94
-
-
22544462786
-
Cardiac changes associated with growth hormone therapy among children treated with anthracyclines
-
Lipshultz SE, Vlach SA, Lipsitz SR, et al. 2005. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 115:1613-22
-
(2005)
Pediatrics
, vol.115
, pp. 1613-1622
-
-
Lipshultz, S.E.1
Vlach, S.A.2
Lipsitz, S.R.3
-
95
-
-
84880389889
-
Cardiotoxicity in childhood cancer survivors: A problem with long-Term consequences in need of early detection and prevention
-
Lipshultz SE, Franco VI, Cochran TR. 2013. Cardiotoxicity in childhood cancer survivors: a problem with long-Term consequences in need of early detection and prevention. Pediatr. Blood Cancer 60:1395-96
-
(2013)
Pediatr. Blood Cancer
, vol.60
, pp. 1395-1396
-
-
Lipshultz, S.E.1
Franco, V.I.2
Cochran, T.R.3
-
96
-
-
84873733744
-
Increasing exercise in long-Term survivors of pediatric cancer and their siblings: Should treatment be a family affair?
-
Steiner R. 2013. Increasing exercise in long-Term survivors of pediatric cancer and their siblings: should treatment be a family affair?. Pediatr. Blood Cancer 60:529-30
-
(2013)
Pediatr. Blood Cancer
, vol.60
, pp. 529-530
-
-
Steiner, R.1
-
98
-
-
0030904457
-
Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience
-
Krischer JP, Epstein S, Cuthbertson DD, et al. 1997. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol. 15:1544-52
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 1544-1552
-
-
Krischer, J.P.1
Epstein, S.2
Cuthbertson, D.D.3
-
99
-
-
0028989408
-
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
-
Lipshultz SE, Lipsitz SR, Mone SM, et al. 1995. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. 332:1738-43
-
(1995)
N. Engl. J. Med.
, vol.332
, pp. 1738-1743
-
-
Lipshultz, S.E.1
Lipsitz, S.R.2
Mone, S.M.3
-
100
-
-
77955290396
-
Cardiac function in 5-year survivors of childhood cancer: A long-Term follow-up study
-
van der Pal HJ, van Dalen EC, Hauptmann M, et al. 2010. Cardiac function in 5-year survivors of childhood cancer: a long-Term follow-up study. Arch. Intern. Med. 170:1247-55
-
(2010)
Arch. Intern. Med.
, vol.170
, pp. 1247-1255
-
-
Van Der Pal, H.J.1
Van Dalen, E.C.2
Hauptmann, M.3
-
101
-
-
34250641127
-
Anthracycline-induced cardiotoxicity: Course, pathophysiology, prevention and management
-
Barry E, Alvarez JA, Scully RE, et al. 2007. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin. Pharmacother. 8:1039-58
-
(2007)
Expert Opin. Pharmacother.
, vol.8
, pp. 1039-1058
-
-
Barry, E.1
Alvarez, J.A.2
Scully, R.E.3
-
103
-
-
84891822955
-
Beta-Adrenergic adaptation in idiopathic dilated cardiomyopathy: Differences between children and adults
-
Lipshultz SE, Wilkinson JD. 2014. Beta-Adrenergic adaptation in idiopathic dilated cardiomyopathy: differences between children and adults. Eur. Heart J. 35:10-12
-
(2014)
Eur. Heart J.
, vol.35
, pp. 10-12
-
-
Lipshultz, S.E.1
Wilkinson, J.D.2
|